Evidence map›Paper›PMID 41438155›Full record

ReviewFrontiers in drug delivery2025

Use of encapsulated dexamethasone sodium phosphate (eDSP) in chronic obstructive pulmonary disease, cystic fibrosis, and inflammatory bowel disorders.

Biljana Horn, Giovanni Mambrini, Maureen Roden, Caralee Schaefer, Dirk Thye, Mauro Magnani

Abstract readReview
In one paragraph

Review in Frontiers in drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Biljana HornQuince Therapeutics, Inc., South San Francisco, CA, United States.
Giovanni MambriniQuince Therapeutics, Inc., South San Francisco, CA, United States.
Maureen RodenQuince Therapeutics, Inc., South San Francisco, CA, United States.
Caralee SchaeferQuince Therapeutics, Inc., South San Francisco, CA, United States.
Dirk ThyeQuince Therapeutics, Inc., South San Francisco, CA, United States.
Mauro MagnaniDepartment of Biomolecular Sciences, University of Urbino, Urbino, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucocorticoids are cornerstone treatment for inflammatory diseases but are limited by systemic toxicity from high-dose and prolonged use. Encapsulation of dexamethasone sodium phosphate (DSP) in autologous erythrocytes aims for sustained drug release with an improved safety profile. This manuscript summarizes early clinical studies of encapsulated DSP (eDSP) in pulmonary and inflammatory bowel disorders (IBD). From 2001 to 2013, eight clinical studies investigated eDSP in patients whose age ranged from 5 to 83 years, with chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), Crohn's disease (CD), and ulcerative colitis (UC). DSP was loaded into autologous erythrocytes

Indexed as

chronic obstructive pulmonary diseasecystic fibrosisEryDexerythrocyte encapsulated dexamethasone sodium phosphate (eDSP)inflammatory bowel diseaseosmotic encapsulation

Identifiers

PMID41438155
PMCPMC12719489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.